Investing.com - Lineage Cell Therapeutics reported on Thursday third quarter earnings that missed analysts' forecasts and revenue that fell short of expectations.
Lineage Cell Therapeutics announced earnings per share of $-0.040 on revenue of $3M. Analysts polled by Investing.com EPS of $-0.030 on revenue of $3.82M.
Lineage Cell Therapeutics 's are down 28.35% and is trading at $1.320 , still down 50.92% from its 52 week high of $2.71 set on Monday, December 27, 2021.
Lineage Cell Therapeutics shares lost 0.75% to trade at $1.320 in after-hours trade the report.
Lineage Cell Therapeutics follows other major Healthcare sector earnings this month
Lineage Cell Therapeutics's report follows an earnings beat by UnitedHealth on Friday, October 14, 2022, who reported EPS of $5.79 on revenue of $80.89B, EPS of $5.43 on revenue of $80.52B.
J&J had beat expectations on Tuesday, October 18, 2022 with third quarter EPS of $2.55 on revenue of $23.79B, for EPS of $2.52 on revenue of $23.46B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar